AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Curis, Inc.
Video analysis: CRIS
All videosNo video analysis for this stock yet. Request one from our team.
News: CRIS
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the "Offering").
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia (CLL).
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass.
Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
Similar companies
-
Processa Pharmaceuticals, Inc.
PCSA
·
NASDAQ
Compare
-
BriaCell Therapeutics Corp.
BCTX
·
NASDAQ
Compare
-
Citius Pharmaceuticals, Inc.
CTXR
·
NASDAQ
Compare
-
Palisade Bio, Inc.
PALI
·
NASDAQ
Compare
-
Aspire Biopharma Holdings, Inc.
ASBP
·
NASDAQ
Compare
-
SeaStar Medical Holding Corporation
ICU
·
NASDAQ
Compare